Development Neuren Pharmaceuticals (NEU-ASX) | Speculative Buy | Valuation: AUD7.70This is a key result in line with our research thesis.Trofinetide (formerly NNZ-2566) is Neuren’s primary asset and has been exclusively licensed to Acadia Pharmaceuticals (NASDAQ:ACAD) for North America. Today Acadia announced a robustly positive Phase 3 clinical trial outcome.This result derisks NEU and adds ~40% to our valuation at initiation.
report
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.26 |
Change
0.010(0.05%) |
Mkt cap ! $2.591B | |||
| Open | High | Low | Value | Volume |
| $20.40 | $20.50 | $20.17 | $1.278M | 62.94K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 3120 | $20.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.27 | 153 | 5 |
View Market Depth
| Last trade - 12.20pm 08/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$20.23 |
Change
0.010 ( 0.01 %) |
||||
| Open | High | Low | Volume | ||
| $20.45 | $20.50 | $20.16 | 22681 | ||
| Last updated 12.40pm 08/05/2024 ? | |||||
| NEU (ASX) Chart |